Low HDL-The Challenge

Area of Science:

• Cardiology
• Metabolic Syndrome
• Lipid Metabolism

Background:

• High-density lipoprotein (HDL) removes low-density lipoprotein (LDL) via reverse cholesterol transport and possesses anti-inflammatory/antioxidant properties.
• Low HDL levels are an independent risk factor for coronary artery disease (CAD).
• Management of low HDL involves lifestyle changes, metabolic syndrome control, and exercise.

Purpose of the Study:

• To review current strategies for managing low high-density lipoprotein (HDL) levels.
• To evaluate the efficacy of pharmacological interventions aimed at increasing HDL levels and function.
• To determine the optimal approach for patients with low HDL and increased cardiovascular risk.

Main Methods:

• Review of clinical guidelines and landmark studies on HDL management.
• Analysis of pharmacologic interventions targeting HDL, including cholesteryl ester transfer protein (CETP) inhibitors and apolipoprotein A1 infusion.
• Evaluation of lifestyle modifications, smoking cessation, and statin therapy effects on HDL levels.

Main Results:

• Lifestyle modifications like smoking cessation can improve HDL by 5-10%.
• Statin therapy increases HDL by at least 5% while lowering LDL.
• Pharmacological attempts to raise HDL via CETP inhibition (dalcetrapib, evacetrapib, anacetrapib) or apolipoprotein A1 infusion have shown limited or no clinical benefit in large trials.

Conclusions:

• Current pharmacologic strategies to significantly increase HDL and improve cardiovascular outcomes have been unsuccessful.
• Aggressively lowering low-density lipoprotein (LDL) may be the most effective strategy for patients with low HDL.
• A comprehensive approach including lifestyle changes and optimal LDL reduction is recommended for managing patients at risk due to low HDL.